ArcaArca
Dashboard
All boards
Loading...
PatientsTasksProgram PerformanceRegistry
Settings
  1. Home
  2. Tumor Boards
  3. Board
  4. Session

Breast Oncology Tumor Board

Sat, Apr 18, 2026 · 07:30 · Conference Room A

In Progress
0
Case 2 of 5 · 0 discussed

0 of 5 presented

Sharma, Priya

MRN-001009·48y

Presenting

Dr. Michael Chen

Invasive Ductal Carcinoma, HER2+·Stage IIIA
BiomarkersER−/PR−/HER2+ · Ki-67 42%
HistologyInvasive Ductal Carcinoma · Grade 3
Path StagepT3N1M0
MarginsNegative
Key LabsHemoglobin 13.5Platelets 226
Prior Tx—

Highlighted Path

Sharma, Priya

Invasive Ductal Carcinoma · Stage IIIA · ER-/PR-/HER2+ (IHC 3+), Ki-67 42%, FISH amplified

NCCN Breast Cancer

v4.2025

Breast Cancer
DCIS (Non-invasive)
Stage 0
Lumpectomy → ± WBRT → ± Endocrine
Mastectomy → ± Endocrine
Invasive
Early Stage (I–IIA)
HR+/HER2−
Surgery → Endocrine ± Chemo
HR+/HER2+
Surgery → TCH(P) → Endocrine
HR−/HER2+
Surgery → TCH(P)
Triple Negative
Surgery → AC-T
Locally Advanced (IIB–III)
HR+/HER2−
Neoadjuvant Chemo → Surgery → Endocrine
HER2+
Neoadjuvant TCHP → Surgery → HER2 maintenance
Triple Negative
Neoadjuvant Chemo + Pembrolizumab → Surgery
Metastatic (IV)
HR+/HER2−
Endocrine + CDK4/6i (1L)
HER2+
Taxane + Trastuzumab + Pertuzumab (1L)
Triple Negative
Chemo + Pembrolizumab (PD-L1+)
Patient pathway Other pathways
12 treatment approaches mapped
Case 2 of 500:00
Clinical question

52-year-old with HER2+ IIB breast cancer, excellent response on neoadjuvant THP (residual 0.8cm). Discuss de-escalation strategy — T-DM1 vs. continuation of HP given near-pCR. Factor in cardiac function (LVEF 58%).

Loading guidelines…
Owner
0 recommendations confirmed